1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously

 
• By Joseph Haas

Biotech thinks its PPAR delta agonist will prove much more potent than Genfit’s elafibranor from the same class and will offer a better tolerability profile than Intercept’s OCA.

Sujal Shah of CymaBay Pharmaceuticals.
CymaBay CEO Sujal Shah

CymaBay Therapeutics Inc. is taking a similar route to market with its PPAR delta agonist seladelpar as Intercept Pharmaceuticals Inc. took with obeticholic acid (OCA) – and with a drug that is the same class as Genfit SA, another market leader. CymaBay hopes to obtain approval first in primary biliary cholangitis (PBC), as Intercept did, and then move on to non-alcoholic steatohepatitis (NASH).

Seladelpar is a selective agonist of peroxisome proliferator-activated receptor delta (PPAR delta), while Genfit’s elafibranor, in Phase III in NASH...

More from Alimentary/Metabolic

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

More from Therapy Areas

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.